Open AccessRetrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center ‘Real-Life’ Experience
Author(s) -
Murat Özbalak,
Metban Mastanzade,
Özden Özlük,
Tarık Onur Tiryaki,
İpek Yönal Hindilerden,
Mustafa Nuri Yenerel,
Ali Altay,
Gülçin Yeğen,
İpek Güngör Doğan,
Meliha Nalçacı,
Sevgi Kkalayoğlu Beşişik
Publication year - 2020
Publication title -
bakırköy tıp dergisi
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.121
H-Index - 4
eISSN - 1305-9327
pISSN - 1305-9319
DOI - 10.5222/bmj.2020.28290
Subject(s) - medicine , gastroenterology , anaplastic large cell lymphoma , lymphoma , chop , bone marrow , single center , retrospective cohort study , b symptoms
Objective: Peripheral T-cell lymhomas (PTCLs) represent a heterogeous group of diseases, with poor long-term outcomes excluding ALK+ anaplastic large cell lymphoma (ALCL). Method: We represent data of our retrospective analysis of 62 consecutive PTCL cases diagnosed since 2002. Median observation time was 16 months. Results: The overall response rate to first line treatment was 53 percent. Data related to median progression- free survival and overall survival times could not be obtained for ALK+ALCL group whereas median progression- free survival and overall survival times for ALK-negative ALCL group were 1 and 18 months, respectively. Disease progression was frequently observed histologically in ALK-negative group. For ALKnegative ALCL, advanced stage disease was defined as the presence of serum albumin 200 ng/ml, presence of B symptoms, and extranodal involvement of more than one site. Risk factors associated with death were serum albumin <3.4 g/dl, serum total protein ≤6.2 g/dl, serum ferritin over 200 ng/ml, and bone marrow involvement at the time of diagnosis. During follow-up 39 patients (64%) died. Most common reasons were progressive disease and infections. Four patients developed secondary malignancies. Conclusion: Our study is a reflection of the ‘real-life’. Three patients died due to disease progression shortly after diagnosis without providing treatment due to aggressiveness of the disease. Alternatives to CHOP-based chemotherapies should be found for the ALK + non-anaplastic large cell lymphoma group.